Live Breaking News & Updates on Clinical laboratory improvement amendments

Stay informed with the latest breaking news from Clinical laboratory improvement amendments on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical laboratory improvement amendments and stay connected to the pulse of your community

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes

...

California , United-states , San-carlos , Texas , Alexey-aleshin , Natera-inc , Nasdaq , Clinical-laboratory-improvement-amendments , Nature-medicine , New-england-journal , Markets ,

IntegraGen: Annual Results 2023 - Positive EBITDA Reflecting Tight Cost Control

Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activities



Positive EBITDA for the third year running, despite inflation impacting reagent...

Germany , France , Paris , France-general- , United-states , Spain , United-kingdom , American , Institut-pasteur , Bernard-courtieu , College-of-american-pathologists , Clinical-laboratory-improvement-amendments

Individual Research Results Should Be Shared With Participants More Often - NAS

Individual Research Results Should Be Shared With Participants More Often - NAS
science20.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science20.com Daily Mail and Mail on Sunday newspapers.

Salt-lake-city , Utah , United-states , Vermont , Columbia-university , New-york , Rockefeller-university , Washington , Pelham-manor , Burlington , Michigan , Baylor-university

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

AUSTIN, Texas, April 11, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here.

Texas , United-states , San-carlos , California , Jonathan-bromberg , Samaniego-picota-milagros , Sangeeta-bhorade , Natera-inc , Nasdaq , Clinical-laboratory-improvement-amendments , University-of-maryland-school-medicine , Drug-administration

Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment
BURLINGTON, N.C., April 10, 2024 /PRNewswire/...

United-states , Brian-caveney , Labcorp-mpox , Centers-for-disease , Clinical-laboratory-improvement-amendments , Drug-administration , Emergency-use-authorization , Home-collection-kit , Labcorp-ondemand , Disease-control , West-african , Federal-food

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers Dr. Blouw is an expert in CNS tumor biology and in the diagnosis of neoplasms of the cerebrospinal fluid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (

Utrecht , Netherlands , California , United-states , San-diego-division , Texas , San-antonio , American , Sb-kolitz-ctrc-zachry , Corey-davis , Barbara-blouw , Andrew-brenner

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics

...

California , United-states , Texas , Germany , San-carlos , German , Sangeeta-bhorade , Coll-cardiol , Shriprasadr-deshpande , Health-resources , Nasdaq , Heart-transplant-program